Argenx Se (ARGX) Non-Current Assets (2015 - 2026)
Argenx Se's (ARGX) quarterly Non-Current Assets came in at $2.0 billion in Q2 2026, up 100.03% YoY from $981.8 million in Q2 2025, and up 10.09% on a QoQ basis from $1.8 billion in Q4 2025.
Argenx Se (ARGX) Non-Current Assets (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Non-Current Assets data on file, last reported at $2.0 billion in Q2 2026.
- Quarterly Non-Current Assets rose 100.03% year-over-year to $2.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$5817.5 billion (changed 0.06% YoY) and the FY2025 annual result came in at $1.8 billion, up 35.21% from the prior year.
- Non-Current Assets climbed to $2.0 billion in Q2 2026, from $1.8 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $2.0 billion in Q2 2026 to a low of -$5822.6 billion in Q2 2025.
- A 5-year average of -$646.2 billion and a median of $502.3 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets soared 215.11% — and 2025, when it tumbled 1092985.0%.
- Tracing ARGX's Non-Current Assets over 5 years: stood at $360.1 million in 2022, then climbed by 16.29% to $418.7 million in 2023, then soared by 215.11% to $1.3 billion in 2024, then surged by 35.21% to $1.8 billion in 2025, then climbed by 10.09% to $2.0 billion in 2026.
- The last three Non-Current Assets figures came in at $2.0 billion (Q2 2026), $1.8 billion (Q4 2025), and -$5822.6 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 564.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.96 Bn |
| Dec 31, 2025 | 1.78 Bn |
| Jun 30, 2025 | -5,822.56 Bn |
| Dec 31, 2024 | 1.32 Bn |
| Jun 30, 2024 | 532.77 Mn |
| Dec 31, 2023 | 418.72 Mn |
| Jun 30, 2023 | 502.28 Mn |
| Dec 31, 2022 | 360.06 Mn |
| Jun 30, 2022 | 319.95 Mn |
| Dec 31, 2021 | 307.30 Mn |
| Jun 30, 2021 | 348.36 Mn |
| Dec 31, 2020 | 216.26 Mn |
| Jun 30, 2020 | 71.45 Mn |
| Dec 31, 2019 | 66.55 Mn |
| Jun 30, 2019 | 55.35 Mn |
| Dec 31, 2018 | 6.87 Mn |
| Jun 30, 2018 | 5.08 Mn |
| Dec 31, 2017 | 4.83 Mn |
| Jun 30, 2017 | 3.93 Mn |
| Dec 31, 2016 | 4.30 Mn |